Ophir Shahaf

Ehealth Ventures Israel Ltd (eHealth Ventures) is a venture capital firm founded in 2014 by Stephen Shapiro. The firm is headquartered in Tel Aviv, Israel.

Hadasit Bio-Holdings Ltd. /Private Equity/ (Hadasit Bio-Holdings /Private Equity/) is a private equity division of Hadasit Bio-Holdings Ltd. founded in 2005. The firm is headquartered in Jerusalem, Israel.

Thrombotech Ltd. is an Israel-based biotechnological company that is based on years of cutting-edge thrombotic research at the Hadassah Medical Center in Jerusalem. Thrombotech developed a peptide called THR-18, which allows the existing thrombolytic stroke medication to easily dissolve blood clots, extending its short therapeutic time window and diminishing life-threatening side effects. The company was founded in 2000 and is headquartered in Rehovot, Israel.

Bio-MarCare Technologies Ltd. develops diagnostic kits based on novel biomarkers for early cancer identification, monitoring and assistance. Its product mCRC-Strat is a personalized medicine assay predicting responsiveness to anti EGFR therapy and Colon-MarCarePlex is a molecular assay (qRT-PCR) comprising a panel of RNA markers that can detect the advanced adenoma polyps as well as early stage colorectal cancer. The company was founded by Beatrice Uziely and Rachel Bar-Shavit in 2002 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Part of Protalix Biotherapeutics, Inc., Protalix Biotherapeutics Ltd. is an Israeli company that develops a proprietary plant cell culture technology and innovative bioreactor system. The company is based in Karmiel, Israel. Protalix Biotherapeutics was acquired by Orthodontix, Inc. on January 03, 2007.